Safety and effectiveness of a new toric presbyopia-correcting posterior chamber silicone intraocular lens

Pepose, Jay S.; Hayashida, Jon; Hovanesian, John; Davies, James; Labor, Phillips Kirk; Whitman, Jeffrey; Carter, Harvey; Colvard, Michael; Buckhurst, Phillip J; Khodai, Omid; Mittleman, David; Feinerman, Gregg

doi:10.1016/j.jcrs.2014.05.043

Cited by 16 publications

(12 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study are consistent with the favorable safety and efficacy outcomes demonstrated in the FDA registration trial of the lens [ 8 ]. The inclusion and exclusion criteria for this study were chosen to have a study population somewhat similar to the study population in the FDA trial yet still reflect real-world clinical practice.…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Visual and Refractive Outcomes of a Toric Presbyopia-Correcting Intraocular Lens

Epitropoulos

2016

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To evaluate outcomes in astigmatic patients implanted with the Trulign (Bausch + Lomb) toric presbyopia-correcting intraocular lens (IOL) during cataract surgery in a clinical practice setting. Methods. Retrospective study in 40 eyes (31 patients) that underwent cataract extraction and IOL implantation in a procedure using intraoperative wavefront aberrometry guidance (ORA system). Endpoints included uncorrected visual acuity (VA), reduction in refractive cylinder, accuracy to target, axis orientation, and safety. Results. At postoperative month 1, refractive cylinder was ≤0.50 D in 97.5% of eyes (≤1.00 D in 100%), uncorrected distance VA was 20/25 or better in 95%, uncorrected intermediate VA was 20/25 or better in 95%, and uncorrected near VA was 20/40 (J3 equivalent) or better in 92.5%. Manifest refraction spherical equivalent was within 1.00 D of target in 95% of eyes and within 0.50 D in 82.5%. Lens rotation was <5° and best-corrected VA was 20/25 or better in all eyes. Conclusion. The IOL effectively reduced refractive cylinder and provided excellent uncorrected distance and intermediate vision and functional near vision. Refractive predictability and rotational stability were exceptional. Implantation of this toric presbyopia-correcting IOL using ORA intraoperative aberrometry provides excellent refractive and visual outcomes in a standard of care setting.

show abstract

Section: Discussionsupporting

confidence: 86%

“…The aspheric optic of the parent IOL provides excellent image sharpness [ 6 ] and depth of focus [ 7 ]. On the basis of favorable refractive and visual outcomes in a FDA registration trial [ 8 ], in 2013, the Trulign toric IOL became the first premium presbyopia-correcting toric IOL available for use in the United States.…”

Section: Introductionmentioning

confidence: 99%

Visual and Refractive Outcomes of a Toric Presbyopia-Correcting Intraocular Lens

Epitropoulos

2016

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The incidence of PCO has been reduced, but not eliminated, by more extensive removal or repositioning of lens tissue during surgery, advances in the composition and conformation of IOLs, and posterior capsulorhexis. 8,13,[44][45][46][47][48][49] While certain drugs may impede the initial response of cells to surgery, it is uncertain whether they would continue to block development of PCO that may arise months or years later. 13,20,[50][51][52] Cytotoxic drugs and chemicals that nonspecifically kill cells at the time of surgery and extensive removal of lens epithelial cells may cause the IOL to be more mobile, and drugs may diffuse to surrounding ocular tissues and initiate an inflammatory response to necrotic tissue.…”

Section: Discussionmentioning

confidence: 99%

Depletion of Myo/Nog Cells in the Lens Mitigates Posterior Capsule Opacification in Rabbits

Gerhart

Werner

Mamalis

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. Posterior capsule opacification (PCO) is a vision-impairing disease that occurs in some adults and most children after cataract surgery. Contractile myofibroblasts contribute to PCO by producing wrinkles in the lens capsule that scatter light. Myofibroblasts in the lens originate from Myo/Nog cells named for their expression of the MyoD transcription factor and bone morphogenetic protein inhibitor noggin. In this study we tested the effects of depleting Myo/Nog cells on development of PCO. METHODS. Myo/Nog cells were eliminated by injecting the G8 antibody conjugated to 3DNA nanocarriers for the cytotoxin doxorubicin (G8:3DNA:Dox) during cataract surgery in rabbits. The severity of PCO was scored by slit lamp analysis, gross and histologic observation, and immunofluorescence localization of a-smooth muscle actin. RESULTS. G8:3DNA:Dox specifically induced cell death in Myo/Nog cells in the lens. None of the lenses administered G8:3DNA containing 9 to 36 lM doxorubicin developed greater than trace levels of central PCO and few myofibroblasts were present on the capsule. Less than 9% of these lenses exhibited greater than mild levels of peripheral PCO. Doxorubucin itself reduced PCO; however, myofibroblasts and wrinkles were abundant in the lens, and off-target effects were observed in the ciliary processes and cornea. CONCLUSIONS. Myo/Nog cells are the primary source of myofibroblasts in the lens after cataract surgery. Targeted depletion of Myo/Nog cells has potential for preventing PCO and preserving vision.

show abstract

“…A decrease in contrast sensitivity is a side effect of diffractive multifocal IOLs compared with monofocal IOLs. 9,19,20 HOAs and MTFs were measured by the i-Trace based on ray tracing and compared between groups in this study to evaluate the potential effect on the visual and ocular optical quality. The level of HOA is difficult to express when aberrometry is performed for multifocal lenses, 21 and ray tracing seems to be the most adequate platform.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Visual Performance After Implantation of Bifocal and Trifocal Intraocular Lenses Having an Identical Platform

Liu¹,

Xie²,

Huang³

2018

J Refract Surg

View full text Add to dashboard Cite

show abstract

Safety and effectiveness of a new toric presbyopia-correcting posterior chamber silicone intraocular lens

Cited by 16 publications

References 29 publications

Visual and Refractive Outcomes of a Toric Presbyopia-Correcting Intraocular Lens

Visual and Refractive Outcomes of a Toric Presbyopia-Correcting Intraocular Lens

Depletion of Myo/Nog Cells in the Lens Mitigates Posterior Capsule Opacification in Rabbits

Comparison of the Visual Performance After Implantation of Bifocal and Trifocal Intraocular Lenses Having an Identical Platform

Contact Info

Product

Resources

About